A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.

Participation in this study will last about 8 weeks, including screening and follow-up.

Inclusion Criteria:

• Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
• Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
• Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening

Exclusion Criteria:

• Participants who have a known clinically significant gastric emptying abnormality
• Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
• Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists